In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

This was the basis to develop a comprehensive single-cell RNA-sequencing atlas of the MM- tumor-immune microenvironment in ...

Researchers at the University of Michigan Rogel Cancer Center have discovered a key reason why some cancers do not respond to ...

Scientists at Pohang University of Science and Technology (POSTECH) and ShanghaiTech University have achieved a breakthrough ...

Researchers discovered that ovarian tumors hinder T cells' energy supply by trapping a key protein, blocking lipid uptake. A ...

Israeli researchers and their colleagues from the United States developed an antibody-based treatment that empowers the ...

Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...

Researchers say study offers proof-of-concept that targeting how T cells interact with metabolites in their environment can ...

Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this ...

"There are impediments to getting the immune cells to where the tumors cells ... that create a heterogeneous target." ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...